SEQIRUS has announced that the 2018 Afluria Quad vaccine is now available in the private market for use in people aged 18 years plus.
The 2018 Southern Hemisphere Afluria Quad formulation contains four influenza strains recommended by the World Health Organization and the Australian Influenza Vaccine Committee.
Following last year's season the 2018 vaccine includes an updated H3N2 strain which was a leading cause of disease last year.
Alongside the private market Afluria Quad will also be made available for eligible people 18-64 years of age on the National Immunisation Program.
The above article was sent to subscribers in Pharmacy Daily's issue from 01 Mar 18
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 01 Mar 18
